STOCK TITAN

[Form 4] CHEMED CORP Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Kevin J. McNamara, President, CEO and a director of Chemed Corporation (CHE), reported an open-market sale of 3,000 shares of Chemed common stock on 09/26/2025. The reported weighted-average sale price was $461.28 per share (transactions ranged from $460.03 to $462.44). After the sale the reporting person beneficially owned 96,197 shares. The Form 4 includes an offer to provide transaction-level price/volume details on request.

Kevin J. McNamara, presidente, CEO e amministratore di Chemed Corporation (CHE), ha riportato una vendita sul mercato aperto di 3.000 azioni ordinarie Chemed in data 26/09/2025. Il prezzo medio ponderato di vendita riportato è stato di $461,28 per azione (le transazioni variavano da $460,03 a $462,44). Dopo la vendita, il soggetto riferente deteneva beneficialmente 96.197 azioni. Il modulo 4 include un’offerta di fornire dettagli sul prezzo/volume a livello di transazione su richiesta.

Kevin J. McNamara, presidente, CEO y director de Chemed Corporation (CHE), informó de una venta en el mercado abierto de 3,000 acciones ordinarias de Chemed en fecha 26/09/2025. El precio de venta medio ponderado reportado fue de $461.28 por acción (las transacciones oscilaron entre $460.03 y $462.44). Tras la venta, la persona reportante poseía beneficiosamente 96,197 acciones. El Formulario 4 incluye una oferta para proporcionar detalles de precio/volumen a nivel de transacción a solicitud.

케빈 J. 맥나마라, Chemed Corporation(CHE)의 회장 겸 CEO이자 이사로, 2025년 9월 26일에 Chemed 일반 주식의 공개시장 매도를 공시했습니다. 보고된 가중평균 매매가는 주당 $461.28였고(거래가는 $460.03에서 $462.44까지). 매도 후 보고자는 보유 주식 수가 96,197주로 증가했습니다. Form 4에는 요청 시 거래 단위의 가격/수량 상세 정보를 제공하겠다는 제안이 포함되어 있습니다.

Kevin J. McNamara, président, CEO et administrateur de Chemed Corporation (CHE), a annoncé une vente sur le marché libre de 3 000 actions ordinaires Chemed le 26/09/2025. Le prix de vente moyen pondéré indiqué était de $461,28 par action (les transactions allaient de $460,03 à $462,44). Après la vente, la personne faisant l’objet du rapport détenait Beneficiairement 96 197 actions. Le Formulaire 4 comprend une offre de fournir des détails sur les prix et volumes par transaction sur demande.

Kevin J. McNamara, Präsident, CEO und Direktor der Chemed Corporation (CHE), meldete einen Handel außerhalb der Börse mit 3.000 Stammaktien von Chemed am 26.09.2025. Der gemeldete gewichtete Verkaufspreis betrug $461,28 pro Aktie (Transaktionen lagen zwischen $460,03 und $462,44). Nach dem Verkauf besaß die meldende Person vorteilhaft 96.197 Aktien. Das Formular 4 enthält ein Angebot, auf Anfrage transaktionsspezifische Preis-/Volumen-Details bereitzustellen.

كيفن J. مكنامارا، رئيس مجلس الإدارة والمدير التنفيذي وعضو مجلس Chemed Corporation (CHE)، أبلغ عن بيع في السوق المفتوحة لـ 3,000 من أسهم Chemed العادية بتاريخ 26/09/2025. كان سعر البيع المتوسط المرجّح المبلغ عنه $461.28 للسهم (التعاملات تراوحت بين $460.03 و $462.44). بعد البيع، امتلك الشخص المُبلغ عنه فعلياً 96,197 سهماً. يتضمن النموذج 4 عرضاً لتوفير تفاصيل السعر/الحجم على مستوى الصفقة عند الطلب.

凯文 J. 麦克纳马拉,Chemed Corporation(CHE)的总裁、首席执行官兼董事,报告在公开市场出售 Chemed 普通股 3,000 股,日期为 2025/09/26。报告的加权平均出售价格为每股 $461.28(交易价格在 $460.03 至 $462.44 之间)。出售后,报告人实际持有 96,197 股。Form 4 包含可应要求提供按交易级别的价格/成交量详情的提议。

Positive
  • None.
Negative
  • Insider disposition: CEO and director sold 3,000 shares on 09/26/2025, reducing beneficial ownership to 96,197 shares.
  • Sale disclosed without context: Form 4 does not state percentage of total holdings sold or use of proceeds, limiting investors' ability to assess intent.

Insights

TL;DR: Insider sale of 3,000 shares at ~$461.28 reduces holdings to 96,197 shares; transaction appears routine and not materially transformative.

The Form 4 discloses a single open-market disposition by CEO Kevin McNamara totaling 3,000 shares at a reported weighted-average price of $461.28 on 09/26/2025. The filing notes multiple execution prices within a narrow range, implying standard block sale execution rather than an exercise-related transfer. The sale represents a specified number of shares but the filing provides no context on percentage of total holdings or intended use of proceeds. Absent additional firmsize-relative metrics, this is a routine disclosure rather than a material corporate development.

TL;DR: Director/CEO reported a small open-market sale; filing meets Section 16 disclosure requirements and includes explanatory footnote.

The submission satisfies Section 16 reporting by specifying the transaction date, quantity, weighted-average price and resulting beneficial ownership. Inclusion of a footnote offering granular trade details is good disclosure practice. There is no indication of related-party transactions or changes to control. From a governance perspective, the filing is compliant and transparent but provides limited information for assessing insider intent.

Kevin J. McNamara, presidente, CEO e amministratore di Chemed Corporation (CHE), ha riportato una vendita sul mercato aperto di 3.000 azioni ordinarie Chemed in data 26/09/2025. Il prezzo medio ponderato di vendita riportato è stato di $461,28 per azione (le transazioni variavano da $460,03 a $462,44). Dopo la vendita, il soggetto riferente deteneva beneficialmente 96.197 azioni. Il modulo 4 include un’offerta di fornire dettagli sul prezzo/volume a livello di transazione su richiesta.

Kevin J. McNamara, presidente, CEO y director de Chemed Corporation (CHE), informó de una venta en el mercado abierto de 3,000 acciones ordinarias de Chemed en fecha 26/09/2025. El precio de venta medio ponderado reportado fue de $461.28 por acción (las transacciones oscilaron entre $460.03 y $462.44). Tras la venta, la persona reportante poseía beneficiosamente 96,197 acciones. El Formulario 4 incluye una oferta para proporcionar detalles de precio/volumen a nivel de transacción a solicitud.

케빈 J. 맥나마라, Chemed Corporation(CHE)의 회장 겸 CEO이자 이사로, 2025년 9월 26일에 Chemed 일반 주식의 공개시장 매도를 공시했습니다. 보고된 가중평균 매매가는 주당 $461.28였고(거래가는 $460.03에서 $462.44까지). 매도 후 보고자는 보유 주식 수가 96,197주로 증가했습니다. Form 4에는 요청 시 거래 단위의 가격/수량 상세 정보를 제공하겠다는 제안이 포함되어 있습니다.

Kevin J. McNamara, président, CEO et administrateur de Chemed Corporation (CHE), a annoncé une vente sur le marché libre de 3 000 actions ordinaires Chemed le 26/09/2025. Le prix de vente moyen pondéré indiqué était de $461,28 par action (les transactions allaient de $460,03 à $462,44). Après la vente, la personne faisant l’objet du rapport détenait Beneficiairement 96 197 actions. Le Formulaire 4 comprend une offre de fournir des détails sur les prix et volumes par transaction sur demande.

Kevin J. McNamara, Präsident, CEO und Direktor der Chemed Corporation (CHE), meldete einen Handel außerhalb der Börse mit 3.000 Stammaktien von Chemed am 26.09.2025. Der gemeldete gewichtete Verkaufspreis betrug $461,28 pro Aktie (Transaktionen lagen zwischen $460,03 und $462,44). Nach dem Verkauf besaß die meldende Person vorteilhaft 96.197 Aktien. Das Formular 4 enthält ein Angebot, auf Anfrage transaktionsspezifische Preis-/Volumen-Details bereitzustellen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
MCNAMARA KEVIN J

(Last) (First) (Middle)
2600 CHEMED CENTER
255 EAST 5TH STREET

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHEMED CORP [ CHE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
president and CEO
3. Date of Earliest Transaction (Month/Day/Year)
09/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Capital Stock 09/26/2025 S 3,000 D $461.28(1) 96,197 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $460.03 to $462.44. The reporting person undertakes to provide to Chemed Corporation, any security holder of Chemed Corporation, or staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) of this Form 4.
Kevin J. McNamara 09/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CHE insider Kevin J. McNamara report on Form 4?

The filing reports an open-market sale of 3,000 Chemed shares on 09/26/2025 at a weighted-average price of $461.28, leaving 96,197 shares beneficially owned.

What price range did the CHE sale occur at?

The Form 4 footnote states transactions executed between $460.03 and $462.44, with a reported weighted-average price of $461.28.

What is Kevin McNamara's role at CHE as reported on the form?

The filing identifies Kevin J. McNamara as a Director and as an Officer with the title President and CEO.

Does the Form 4 indicate any derivative transactions or amendments?

No derivative securities or amendments are reported; the Form 4 only records the non-derivative sale of common stock on 09/26/2025.

Can investors obtain more granular trade details from the filer?

Yes. The reporting person states they will provide detailed information on the number of shares sold at each separate price within the disclosed range upon request.
Chemed Corp

NYSE:CHE

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

6.74B
14.28M
1.98%
97.98%
2.82%
Medical Care Facilities
Services-home Health Care Services
Link
United States
CINCINNATI